1. Home
  2. SPRO vs VNTG Comparison

SPRO vs VNTG Comparison

Compare SPRO & VNTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRO
  • VNTG
  • Stock Information
  • Founded
  • SPRO 2013
  • VNTG 2012
  • Country
  • SPRO United States
  • VNTG Singapore
  • Employees
  • SPRO N/A
  • VNTG N/A
  • Industry
  • SPRO Biotechnology: Pharmaceutical Preparations
  • VNTG
  • Sector
  • SPRO Health Care
  • VNTG
  • Exchange
  • SPRO Nasdaq
  • VNTG NYSE
  • Market Cap
  • SPRO 162.1M
  • VNTG 142.2M
  • IPO Year
  • SPRO 2017
  • VNTG 2025
  • Fundamental
  • Price
  • SPRO $2.18
  • VNTG $4.30
  • Analyst Decision
  • SPRO Buy
  • VNTG
  • Analyst Count
  • SPRO 4
  • VNTG 0
  • Target Price
  • SPRO $5.00
  • VNTG N/A
  • AVG Volume (30 Days)
  • SPRO 784.3K
  • VNTG 65.6K
  • Earning Date
  • SPRO 08-12-2025
  • VNTG 01-01-0001
  • Dividend Yield
  • SPRO N/A
  • VNTG N/A
  • EPS Growth
  • SPRO N/A
  • VNTG N/A
  • EPS
  • SPRO N/A
  • VNTG 0.14
  • Revenue
  • SPRO $44,584,000.00
  • VNTG $18,659,141.00
  • Revenue This Year
  • SPRO N/A
  • VNTG N/A
  • Revenue Next Year
  • SPRO N/A
  • VNTG N/A
  • P/E Ratio
  • SPRO N/A
  • VNTG $30.68
  • Revenue Growth
  • SPRO N/A
  • VNTG N/A
  • 52 Week Low
  • SPRO $0.51
  • VNTG $3.55
  • 52 Week High
  • SPRO $3.22
  • VNTG $6.09
  • Technical
  • Relative Strength Index (RSI)
  • SPRO 32.49
  • VNTG N/A
  • Support Level
  • SPRO $2.30
  • VNTG N/A
  • Resistance Level
  • SPRO $2.45
  • VNTG N/A
  • Average True Range (ATR)
  • SPRO 0.11
  • VNTG 0.00
  • MACD
  • SPRO -0.07
  • VNTG 0.00
  • Stochastic Oscillator
  • SPRO 2.03
  • VNTG 0.00

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About VNTG VANTAGE CORP

Vantage Corp specializes in providing comprehensive shipbroking services, including operational support and consultancy services, tailored to the tanker markets. The company has divided the services into various division such as Freight commission, Demurrage commission, Deviation and other commission and Sales of vessel commission.

Share on Social Networks: